Diasorin and QIAGEN have announced the launch of the new CE-marked LIAISON QuantiFERON-TB Gold Plus II, a next-generation assay that redefines speed and throughput as an aid in the diagnosis of tuberculosis infection on LIAISON analyser systems.
The new assay enables laboratories to test up to 75% more patients per hour and achieve a 25% faster turnaround time compared to the previous version. This marks a major advance in workflow efficiency and productivity for Mycobacterium tuberculosis diagnostics, combining QIAGEN’s gold-standard QuantiFERON technology with Diasorin’s high-throughput LIAISON platforms — giving laboratories a faster, more efficient solution to meet growing global demand for TB testing.
Latent tuberculosis infection (LTBI) affects roughly 25% of the world’s population, with up to 10% at risk of progressing to active disease if untreated. Faster, scalable testing is essential to achieving World Health Organization targets for TB elimination. The new LIAISON QuantiFERON-TB Gold Plus II provides laboratories with a powerful tool to expand screening access and strengthen global TB prevention efforts.
“With the new LIAISON QuantiFERON-TB Gold Plus II, we are equipping laboratories with a powerful, high-throughput tool to meet growing global demand for TB testing,” commented Chen Even PhD, Chief Commercial Officer of Diasorin. “This next-generation solution optimises the world’s leading latent TB test for automated, high-volume environments. It enables laboratories to screen more at-risk patients efficiently, helping prevent progression to active TB and advancing global TB control initiatives.”
Diasorin and QIAGEN have worked together since 2017 to integrate QuantiFERON technology into the LIAISON family of analysers, combining QIAGEN’s diagnostic leadership with Diasorin’s automation expertise. Today, more than 7,000 LIAISON systems are installed globally, enabling high-volume testing labs to process QuantiFERON-TB Gold Plus II with minimal hands-on time, full traceability and seamless IT integration.